🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

28 results for “SAB” Clear

  1. Inactivated Poliomyelitis Vaccine (Sabin strains)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Poliomyelitis

    phase 3 mab completed

    2 trials

  2. KIOVIG 100 mg/ml solution for infusion, TECVAYLI 90 mg/mL solution for injection, TECVAYLI 10 mg/mL solution for injection, KIOVIG 100 mg/ml solution for infusion

    Takeda

    Primary infection prophylaxis for secondary immunodeficiency (SID) in patients with multiple myeloma (MM) receiving B cell maturation antigen (BCMA)-directed bispecific (BsAb) therapy

    phase 3 small molecule active

    1 trial

  3. Parsabiv 5 mg solution for injection, Parsabiv 10 mg solution for injection

    Amgen

    Secondary hyperparathyroidism (SHPT) in pediatric patients with chronic kidney disease (CKD) in hemodialysis

    phase 3 small molecule active

    1 trial

  4. Sabin Strain Inactivated Poliovirus Vaccine

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 3 mab completed

    1 trial

  5. bamlanivimab 7000mg

    SAB Biotherapeutics

    Coronavirus

    phase 3 mab completed

    1 trial

  6. AZD0780, AZD0780, AZD0780 Placebo, AZD0780

    AstraZeneca AB

    Dyslipidemia Dyslipidemias are alterations to the plasma lipid profile associated often with clinical condition. A common form of dyslipidemia is Hypercholesterolemia due to high level of LDL-cholesterol, which is a major risk factor for Cardiovascular Disease (CVD), such as Ischemic Heart Disease and Ischemic Stroke. CVD is a leading cause of global mortality and a contributor to disability.

    phase 2 small molecule active

    1 trial

  7. High Dose SAB-142

    SAB Biotherapeutics

    Type 1 Diabetes

    phase 2 small molecule active

    1 trial

  8. KN046 （PD-L1/CTLA4 BsAb）

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced HCC

    phase 2 small molecule terminated

    1 trial

  9. La composición cualitativa y cuantitativa de cada sobre de placebo es la siguiente: Bicarbonato sódico 563,75 mg Diluyente/generador de efervescencia Ph Eur Ácido cítrico 410,0 mg Diluyente/generador de efervescencia Ph Eur Maltodextrina 651,25 mg Diluyente Ph Eur Sílice coloidal anhidra 10,0 mg Fluidificante/desecante interno Ph Eur Manitol 769,0 mg Diluyente Ph Eur Sacarina sódica 24,0 mg Edulcorante Ph Eur Aroma de naranja 72,0 mg Saborizante Espec.. interna Masa nominal 2.500 mg El polvo efervescente se

    The George Institute

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  10. Ocrevus 300 mg concentrate for solution for infusion, CYTARABINE, CARMUSTINE, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE, Tysabri 300 mg concentrate for solution for infusion, CARMUSTINE, ETOPOSIDE, CARMUSTINE, UBLITUXIMAB, MELPHALAN FLUFENAMIDE, FILGRASTIM, FILGRASTIM, CYTARABINE, CYTARABINE, CYCLOPHOSPHAMIDE, RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, Kesimpta 20 mg solution for injection in pre-filled pen, ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS, CYTARABINE, LEMTRADA 12 mg concentrate for solution f

    Fondazione Telethon ETS

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  11. SAB-142, SODIUM CHLORIDE

    SAB Biotherapeutics

    Type 1 Diabetes

    phase 2 small molecule active

    1 trial

  12. SAB-176

    SAB Biotherapeutics

    Influenza A H1N1

    phase 2 mab completed

    1 trial

  13. Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)

    Takeda

    Poliomyelitis

    phase 2 mab terminated

    1 trial

  14. sabirnetug

    Acumen Pharmaceuticals

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  15. A study to find out whether the medication pasireotide is absorbed and processed the same way when given under the skin using either a reusable pen or a syringe in healthy subjects

    Recordati Ireland

    Post-bariatric hypoglycaemia

    phase 1 other active

    1 trial

  16. An open-label, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study with GP-IMP-001 in healthy male volunteers under fasting conditions.

    Lacuna Pharma Pty Ltd

    inteneded for treatment of - active rheumatoid arthritis in adult patients, - polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal anti-inflammatory drugs has been inadequate, - severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy and severe psoriatic arthritis in adult patients, - mild-to-moderate Crohn’s disease, either alone or in combination with corticosteroids, in adult patients refractory or intolerant to thiopurines.

    phase 1 other active

    1 trial

  17. SAB-176

    SAB Biotherapeutics

    Influenza Type A

    phase 1 mab completed

    1 trial

  18. SAB-185

    SAB Biotherapeutics

    COVID-19

    phase 1 mab active

    2 trials

  19. SAB-301

    SAB Biotherapeutics

    Middle East Respiratory Syndrome Coronavirus

    phase 1 mab completed

    1 trial

  20. Single Ascending Dose of SAB-176

    SAB Biotherapeutics

    PHA1A

    phase 1 small molecule active

    1 trial

  21. sabirnetug (ACU193)

    Acumen Pharmaceuticals

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  22. Bilaxten Flas 10 mg comprimidos bucodispersables

    A. Menarini Industrie Farmaceutiche Riunite s.r.l.

    Allergic rhinoconjunctivitis

    approved small molecule active

    1 trial

  23. Placebo, Desloratadine 5 mg orodispersible tablets, Bactil Flas 10 mg Liofilizados orales, Bilaxten 20 mg comprimidos bucodispersables

    A. Menarini Industrie Farmaceutiche Riunite s.r.l.

    Allergy

    approved small molecule active

    1 trial

  24. RITALINE L.P. 10 mg, gélule à libération prolongée

    Tour Hekla

    Attention Deficit Disorder with or without Hyperactivity (ADHD) is a neurodevelopmental disorder characterized by disabling symptoms of inattention and/or hyperactivity-impulsivity beginning before the age of 12 with significant personal, social, academic and/or occupational impact (American Psychiatric Association 2013). This disorder, whose prevalence is around 5% in children and adolescents, affects 2.6% of adults (American Psychiatric Association 2013; Song et al. 2021).

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources